alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Federal Register Volume 75, Number 40 (Tuesday, March 2, 2010)]
[Notices]
[Pages 9399-9400]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4274]

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

Corps of Engineers

Notice of Availability of a Final General Conformity 
Determination and Record of Decision for the Middle Harbor 
Redevelopment Project, Port of Long Beach, Los Angeles County, CA

AGENCY: Department of the Army--U.S. Army Corps of Engineers, DoD.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: In April 2009, the U.S. Army Corps of Engineers, Los Angeles 
District, Regulatory Division (Corps) in coordination with the Port of 
Long Beach (POLB) completed and published a joint Final Environmental 
Impact Statement/Environmental Impact Report (EIS/EIR) for the Middle 
Harbor Redevelopment Project (Project) in the

[[Page 9400]]

POLB, including a Draft General Conformity Determination, for the 
Federal action associated with the Project. Comments were received on 
the Final EIS and Draft General Conformity Determination until May 3, 
2009. A General Conformity Determination was required because Project 
construction would require Federal action (i.e., issuance of a Corps 
permit for work and structures in and over navigable waters and 
discharges of fill into waters of the U.S.) and not all the Federal 
action's direct and indirect air emissions would be below specified de 
minimis thresholds (40 CFR 93.153(b)). On February 23, 2010, the Corps 
completed its environmental review and made a Final General Conformity 
Determination, executed the Record of Decision (ROD), and issued a 
Standard Individual Permit for the Federal action associated with the 
Project, pursuant to Section 404 of the Clean Water Act and Section 10 
of the River and Harbor Act. The Corps considered and responded to all 
comments received in making the Final General Conformity Determination, 
executing the ROD, and issuing the Corps permit. The public can request 
copies of the Final General Conformity Determination document or the 
ROD from the Corps at the address listed below, or can view or download 
the these documents from the Corps' Web site (http://www.spl.usace.army.mil/regulatory/POLB.htm).

FOR FURTHER INFORMATION CONTACT: Questions or requests concerning the 
Final General Conformity Determination or the ROD should be directed to 
Antal Szijj, Senior Project Manager, North Coast Branch, Regulatory 
Division, U.S. Army Corps of Engineers, 2151 Alessandro Drive, Suite 
110, Ventura, California 93001, (805) 585-2147.

SUPPLEMENTARY INFORMATION: None.

David J. Castanon,
Chief, Regulatory Division, Los Angeles District.
[FR Doc. 2010-4274 Filed 3-1-10; 8:45 am]
BILLING CODE 3720-58-P
```
#### § 514.6 Amended applications.

The applicant may submit an amendment to an application that is pending, including changes that may alter the conditions of use, the labeling, safety, effectiveness, identity, strength, quality, or purity of the drug or the adequacy of the manufacturing methods, facilities, and controls to preserve them, in which case the unamended application may be considered as withdrawn and the amended application may be considered resubmitted on the date on which the amendment is received by the Food and Drug Administration. The applicant will be notified of such date.
Editorial Note on Part 17
Editorial Note: Nomenclature changes to part 17 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

§ 17.35 Sanctions. ( a ) The presiding officer may sanction a person, including any party or counsel for: ( 1 ) Failing to comply with an order, subpoena, rule, or procedure governing the proceeding;
( 2 ) Failing to prosecute or defend an action; or
( 3 ) Engaging in other misconduct that interferes with the speedy, orderly, or fair conduct of the hearing.
( b ) Any such sanction, including, but not limited to, those listed in paragraphs (c), (d), and (e) of this section, shall reasonably relate to the severity and nature of the failure or misconduct.
( c ) When a party fails to comply with a discovery order, including discovery and subpoena provisions of this part, the presiding officer may: ( 1 ) Draw an inference in favor of the requesting party with regard to the information sought;
( 2 ) Prohibit the party failing to comply with such order from introducing evidence concerning, or otherwise relying upon, testimony relating to the information sought; and
( 3 ) Strike any part of the pleadings or other submissions of the party failing to comply with such request.
( d ) The presiding officer may exclude from participation in the hearing any legal counsel, party, or witness who refuses to obey an order of the presiding officer. In the case of repeated refusal, the presiding officer may grant judgment to the opposing party.
( e ) If a party fails to prosecute or defend an action under this part after service of a notice of hearing, the presiding officer may dismiss the action or may issue an initial decision imposing penalties and assessments.
( f ) The presiding officer may refuse to consider any motion, request, response, brief, or other document that is not filed in a timely fashion or in compliance with the rules of this part.
( g ) Sanctions imposed under this section may be the subject of an interlocutory appeal as allowed in § 17.18(b), provided that no such appeal will stay or delay a proceeding.
# C_2014212EN.01001501.xml

| 7.7.2014 | EN | Official Journal of the European Union | C 212/15 |
| --- | --- | --- | --- |

7.7.2014

EN

Official Journal of the European Union

C 212/15

---

Request for a preliminary ruling from the Inalta Curte de Casaţie şi Justiţie (Romania) lodged on 7 April 2014 — ING Pensii Societate de Administrare a unui Fond de Pensii Administrat Privat SA v Consiliul Concurenței

(Case C-172/14)

2014/C 212/15

Language of the case: Romanian

Referring court

Referring court

Inalta Curte de Casaţie şi Justiţie

Parties to the main proceedings

Parties to the main proceedings

Applicant: ING Pensii Societate de Administrare a unui Fond de Pensii Administrat Privat SA

Applicant:

Defendant: Consiliul Concurenței

Defendant:

Question referred

Question referred

In relation to a practice by virtue of which clients are shared out, is the specific and definitive number of those clients relevant in deciding whether the condition of a significant distortion of competition for the purposes of Article 101(1)(c) TFEU is fulfilled?

---
###### Editorial Note on Part 312

#### Editorial Note:

Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

#### § 312.60 General responsibilities of investigators.

An investigator is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations; for protecting the rights, safety, and welfare of subjects under the investigator's care; and for the control of drugs under investigation. An investigator shall obtain the informed consent of each human subject to whom the drug is administered, in accordance with part 50 of this chapter. Additional specific responsibilities of clinical investigators are set forth in this part and in parts 50 and 56 of this chapter.

[88 FR 88248, Dec. 21, 2023]
<PAGE>   1


                 Consent of Independent Chartered Accountants

We hereby consent to the incorporation by reference in the Registration
Statement on Form S-8 (No. 33-66178) of International Absorbents Inc. of our
report dated March 18, 1998 appearing on page 19 of the Annual Report on Form
10-K for the year ended January 31, 1998.


                                               /S/ PRICE WATERHOUSE

April 25, 1998                                       Charted Accountants
                                                     Vancouver, Canada
#### § 660.5 Specificity.

Each filling of the product shall be specific for antibody to hepatitis B surface antigen, as determined by specificity tests found acceptable by the Director, Center for Biologics Evaluation and Research.

[40 FR 29712, July 15, 1975, as amended at 49 FR 23834, June 8, 1984; 55 FR 11013, Mar. 26, 1990]
### IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 13

- 31158 Summary Calendar

UNITED STATES OF AMERICA , Plaintiff

- Appellee

v. MARCO DILLON , Defendant

- Appellant

Appeal s from the United States District Court for the Eastern District of Louisiana USDC No. 2:12

- CR

- 190

Before SMITH, BARKSDALE, and PRADO, Circuit Judges. PER CURIAM: * Marco Dillon was convicted for conspiracy to distribute , and to possess with the intent to distribute , 28 grams or more , but less than 280 grams , of cocaine base (crack), pursuant to 21 U.S.C. §§ 841(a)(1) , (b)(1)(A) and 846

. In challenging the conviction , Dillon claims the district court erred by admitting certain evidence as intrin sic to the charged conspiracy. (Dillon also claims the evidence is not admissible under Federal Rule of Evidence 40 4(b), concerning

* Pursuant to 5 th Cir. R. 47.5 , the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 th Cir. R. 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED November 13, 2014 Lyle W. Cayce Clerk Case: 13-31158 Document: 00512835652 Page: 1 Date Filed: 11/13/2014No. 13

- 31158
extrinsic evidence. Because, as discussed below, the evidence was intrinsic, we need not reach this second issue.) E vid entiary rulings are reviewed for an abuse of discretion. United States v. Coleman , 78 F.3d 154, 156 (5th Cir. 1996) (citation omitted)

. During the time period of the charged conspiracy , Dillon sold crack cocaine to the same confidential informant who had previously purchased crack cocaine from two of Dillon’s co

- conspirators . Dillon was also arr ested for possession of a scale containing cocaine residue. Th e district court did not abuse its discretion by admi tting the evidence as intrinsic because the contested evidence was relevant to establish the relationship between the co

- conspirators and how the conspiracy was structured and operated

. E.g., United States v. Wood , 58 F.3d 637, 1995 WL 371100 at *5 (5th Cir. 1995) (unpublished but precedential pursuant to 5th Cir. R

. 47.5.3); see also United States v. Watkins , 591 F.3d 780, 784

– 85 (5th Cir. 2009). AFFIRMED.

2 Case: 13-31158 Document: 00512835652 Page: 2 Date Filed: 11/13/2014
§ 640.25 General requirements. ( a ) *Storage.* Immediately after resuspension, Platelets shall be placed in storage at the selected temperature range. If stored at 20 to 24 °C, a continuous gentle agitation of the platelet concentrate shall be maintained throughout the storage period. Agitation is optional if stored at a temperature between 1 and 6 °C.
( b ) *Quality control testing.* Each month four units prepared from different donors shall be tested at the end of the storage period as follows: ( 1 ) Platelet count.
( 2 ) pH of not less than 6.2 measured at the storage temperature of the unit.
( 3 ) Measurement of actual plasma volume.
( 4 ) If the results of the quality control testing indicate that the product does not meet the prescribed requirements, immediate corrective action shall be taken and a record maintained of such action.
( c ) *Manufacturing responsibility.* All manufacturing of Platelets shall be performed at the same licensed establishment, except that the quality control testing under paragraph (b) of this section may be performed by a clinical laboratory which meets the standards of the Clinical Laboratories Improvement Amendments of 1988 (CLIA) (42 U.S.C. 263a) and is qualified to perform platelet counts. Such arrangements must be approved by the Director, Center for Biologics Evaluation and Research, Food and Drug Administration. Such testing shall not be considered as divided manufacturing, as described in § 610.63 of this chapter, provided the following conditions are met: ( 1 ) The results of each test are received within 10 days of the preparation of the platelet concentrate, and are maintained by the establishment licensed for Platelets so that they may be reviewed by an authorized representative of the Food and Drug Administration.
( 2 ) The licensed Platelets manufacturer has obtained a written agreement that the testing laboratory will permit an authorized representative of the Food and Drug Administration to inspect its testing procedures and facilities during reasonable business hours.
( 3 ) The testing laboratory will participate in any proficiency testing programs undertaken by the Center for Biologics Evaluation and Research, Food and Drug Administration.
[40 FR 4304, Jan. 29, 1975, as amended at 47 FR 49021, Oct. 29, 1982; 49 FR 23834, June 8, 1984; 50 FR 4139, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 66 FR 1836, Jan. 10, 2001; 72 FR 45888, Aug. 16, 2007]
IIB 

118TH CONGRESS 

2D SESSION H. R. 7370 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 25, 2024 

Received; read twice and referred to the Committee on Energy and Natural 

Resources 

AN ACT 

To amend the Geothermal Steam Act of 1970 to establish 

a deadline for processing applications related to geothermal leasing. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

HR 7370 RFS

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Geothermal Energy 

3 Opportunity Act’’ or the ‘‘GEO Act’’. 

4 SEC. 2. EFFECT OF PENDING CIVIL ACTIONS ON PROC5 ESSING APPLICATIONS RELATED TO GEO6 THERMAL LEASING. 

7 Section 4 of the Geothermal Steam Act of 1970 (30 

8 U.S.C. 1003) is amended by adding at the end the fol9 lowing: 

10 ‘‘(h) EFFECT OF PENDING CIVIL ACTIONS ON PROC11 ESSING APPLICATIONS RELATED TO GEOTHERMAL LEAS12 ING.— 

13 ‘‘(1) REQUIREMENT TO PROCESS APPLICA14 TIONS.—Notwithstanding the existence of any pend15 ing civil action that affects an application for a geo16 thermal drilling permit, sundry notice, notice to pro17 ceed, right-of-way, or any other authorization under 

18 a valid existing geothermal lease, the Secretary shall, 

19 unless a United States Federal court vacates or pro20 vides injunctive relief for the applicable geothermal 

21 lease, geothermal drilling permit, sundry notice, no22 tice to proceed, right-of-way, or other authorization, 

23 approve and issue, or deny, each such application 

24 not later than 60 days after completing all require25 ments under applicable Federal laws and regula26 tions, including the National Environmental Policy 


ssavage on LAPJG3WLY3PROD with BILLS
3 

HR 7370 RFS

1 Act of 1969, the Endangered Species Act of 1973, 

2 and division A of subtitle III of title 54, United 

3 States Code. 

4 ‘‘(2) NO NEW AUTHORITY FOR FEDERAL

5 COURTS.—Nothing in this subsection shall be con6 strued as modifying any existing authority of a Fed7 eral court to vacate or provide injunctive relief for 

8 a geothermal lease, geothermal drilling permit, sun9 dry notice, notice to proceed, right-of-way, or other 

10 authorization. 

11 ‘‘(3) DEFINITION OF AUTHORIZATION.—In this 

12 subsection, the term ‘authorization’ means any li13 cense, permit, approval, finding, determination, or 

14 other administrative decision issued by a Federal 

15 agency, or any interagency consultation, that is re16 quired or authorized under Federal law or regula17 tions in order to site, construct, reconstruct, or com18 mence operations of a geothermal project adminis19 tered by a Federal agency.’’. 

Passed the House of Representatives September 24, 

2024. 

Attest: KEVIN F. MCCUMBER, 

Clerk. 


ssavage on LAPJG3WLY3PROD with BILLS
§ 343.12 Cardiovascular active ingredients. ( a ) Aspirin.
( b ) Buffered aspirin. Aspirin identified in paragraph (a) of this section may be buffered with any antacid ingredient(s) identified in § 331.11 of this chapter provided that the finished product contains at least 1.9 milliequivalents of acid-neutralizing capacity per 325 milligrams of aspirin as measured by the procedure provided in the United States Pharmacopeia 23/National Formulary 18.
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM AVITAR'S
QUARTERLY REPORT TO STOCKHOLDERS FOR THE QUARTER ENDED DECEMBER 31, 1997 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>1000
       
<S>                                                           <C>
<PERIOD-TYPE>                                                 3-MOS
<FISCAL-YEAR-END>                                             SEP-30-1998
<PERIOD-START>                                                OCT-01-1997
<PERIOD-END>                                                  DEC-31-1997
<CASH>                                                            354,613
<SECURITIES>                                                            0
<RECEIVABLES>                                                     277,494
<ALLOWANCES>                                                        9,000
<INVENTORY>                                                       146,532
<CURRENT-ASSETS>                                                  955,732
<PP&E>                                                            924,234
<DEPRECIATION>                                                    677,997
<TOTAL-ASSETS>                                                  1,216,607
<CURRENT-LIABILITIES>                                           1,707,191
<BONDS>                                                                 0
<PREFERRED-MANDATORY>                                                   0
<PREFERRED>                                                         6,572
<COMMON>                                                          155,627
<OTHER-SE>                                                       (751,204)
<TOTAL-LIABILITY-AND-EQUITY>                                    1,216,607
<SALES>                                                           432,214
<TOTAL-REVENUES>                                                  432,214
<CGS>                                                             421,402
<TOTAL-COSTS>                                                     864,319
<OTHER-EXPENSES>                                                        0
<LOSS-PROVISION>                                                        0
<INTEREST-EXPENSE>                                                 40,436
<INCOME-PRETAX>                                                   667,779
<INCOME-TAX>                                                            0
<INCOME-CONTINUING>                                              (468,391)
<DISCONTINUED>                                                  1,136,170
<EXTRAORDINARY>                                                         0
<CHANGES>                                                               0
<NET-INCOME>                                                      667,779
<EPS-PRIMARY>                                                         .04
<EPS-DILUTED>                                                         .04
        

</TABLE>
I 

118TH CONGRESS 

2D SESSION H. R. 7375 

To amend the Mineral Leasing Act to improve the assessment of expression 

of interest fees, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 15, 2024 

Ms. HAGEMAN introduced the following bill; which was referred to the 

Committee on Natural Resources 

A BILL 

To amend the Mineral Leasing Act to improve the assessment of expression of interest fees, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. FEE FOR EXPRESSION OF INTEREST. 

4 (a) DEADLINE TO ISSUE LEASE.—Section 

5 17(b)(1)(A) of the Mineral Leasing Act (30 U.S.C. 

6 226(b)(1)(A)) is amended by striking ‘‘the remainder of 

7 the bonus bid, if any,’’ and inserting ‘‘, as applicable, the 

8 remainder of the bonus bid, the fee for the expression of 

9 interest under subsection (q)(2)(B),’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7375 IH

1 (b) EXPRESSIONS OF INTEREST.—Section 17(q) of 

2 the Mineral Leasing Act (30 U.S.C. 226(q)) is amended— 

3 (1) in the heading, by striking ‘‘FEE FOR’’; 

4 (2) by redesignating paragraph (2) as para5 graph (3); 

6 (3) by amending paragraph (1) to read as fol7 lows: 

8 ‘‘(1) SUBMISSION OF EXPRESSION OF INTER9 EST.—A person may, in accordance with procedures 

10 established by the Secretary to carry out this sub11 section, submit an expression of interest in leasing 

12 land available for disposition under this section for 

13 exploration for, and development of, oil or gas. 

14 ‘‘(2) ASSESSMENT OF FEES.— 

15 ‘‘(A) NO BID.—If land covered by an ex16 pression of interest submitted under paragraph 

17 (1) is offered at a lease sale and no bid is re18 ceived for such land, the Secretary shall assess 

19 at the time of the sale a fee for the expression 

20 of interest against the person that submitted 

21 the first expression of interest for the land. 

22 ‘‘(B) SUCCESSFUL BID.—If land covered 

23 by an expression of interest submitted under 

24 paragraph (1) receives a successful bid at a 

25 lease sale, the Secretary shall assess a fee for 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 7375 IH

1 the expression of interest against the successful 

2 bidder.’’; 

3 (4) in paragraph (3), as so redesignated, by 

4 striking ‘‘paragraph (1)’’ and inserting ‘‘paragraph 

5 (2)’’; and 

6 (5) by adding at the end the following: 

7 ‘‘(4) TERM.—An expression of interest sub8 mitted under this section shall remain active for a 

9 term of not less than 5 years unless the land covered 

10 by the expression of interest is offered at a lease 

11 sale.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States

              																								United States. Congress. Joint Economic Committee, 1956-					 and 	Eighty-Sixth Congress, 1959-1961.						"Study Paper No. 20 : The Potential Economic Growth in the United State" in *Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States*			(January 30, 1960).						https://fraser.stlouisfed.org/title/1244/item/3645, accessed on September 26, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER